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Abstract
Background: Extracts of chicory root have anti-inflammatory properties in vitro and in animal models of arthritis. The 
primary objective of this investigator-initiated, Phase 1, placebo-controlled, double blind, dose-escalating trial was to 
determine the safety and tolerability of a proprietary bioactive extract of chicory root in patients with osteoarthritis 
(OA). Secondary objectives were to assess effects on the signs and symptoms of this disorder.
Methods: Individuals greater than 50 years of age with OA of the hip or knee were eligible for trial entry. A total of 40 
patients were enrolled in 3 cohorts and were treated with escalating chicory doses of 600 mg/day, 1200 mg/day and 
1800 mg/day for 1 month. The ratio of active treatment to placebo was 5:3 in cohorts 1 and 2 (8 patients) each and 16:8 
in cohort 3 (24 patients). Safety evaluations included measurement of vital signs and routine lab tests at baseline and 
the end of the treatment period. Efficacy evaluations at baseline and final visits included self-assessment 
questionnaires and measurement of the 25-foot walking time.
Results: In the highest dose cohort, 18 patients who completed treatment per protocol were analyzed for efficacy. In 
this group, 13 patients showed at least 20% improvement in the defined response domains of pain, stiffness and global 
assessment: 9 of 10 (90%) patients randomized to active treatment with chicory and 4 of 8 (50%) patients randomized 
to placebo (P = 0.06). In general, the treatment was well-tolerated. Only one patient who was treated with the highest 
dose of chicory had to discontinue treatment due to an adverse event.
Conclusions: The results of this pilot study suggest that a proprietary bioactive extract of chicory root has a potential 
role in the management of OA and merits further investigation. Clinicaltrials.gov identifier: NCT 01010919.
Background
Osteoarthritis (OA) is the most common form of arthritis
and it is increasing in prevalence as the population ages
[1]. Disability costs related to OA are significant and this
condition is the most common indication for joint
replacement of the hip or knee [2]. Treatment regimens
for OA alleviate symptoms but do not modify the course
of the disease. The most frequently used agents are non-
steroidal anti-inflammatory drugs (NSAIDs) and acet-
aminophen. Controlled studies have suggested that
treatments that have anti-inflammatory properties pro-
vide greater symptom relief than analgesics alone [3].
However, the NSAIDs that are usually used have adverse
effects [4] and in recent years the use of Cox-2-selective
agents has been shown to be associated with an increased
risk of cardiovascular morbidity and mortality [5]. These
treatment issues have led to increased interest in alterna-
tive therapies that might offer relief of symptoms with
fewer side effects. Nutritional supplements of many types
have been utilized for arthritis, and those containing glu-
cosamine and chondroitin sulfate have been shown to
provide pain relief [6]. Other supplements have been
tried, but evidence in favor of their use is generally lim-
ited to anecdotal experience or in vitro effects [7,8].
We were interested in evaluating effects of a proprie-
tary bioactive extract of chicory root in patients with OA,
based on in vitro data demonstrating its anti-inflamma-
tory properties including inhibition of the production of
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Page 2 of 7COX-2 [9], iNOS, TNF-α and NFκB [9,10]. Pre-clinical
toxicology studies have shown no adverse effects in
rodents [10]. Chicory has a long history of use for other
medical conditions such as digestive disorders, it has for
many years been added to food products like coffee and it
has a very good safety profile. If chicory could alleviate
some of the signs and symptoms of OA while having
fewer side effects than NSAIDs, we postulated that it
would have clinical utility.
The present study was designed to evaluate safety and
tolerability of treatment with a proprietary bioactive
extract of chicory root in patients with OA of the hip or
knee evaluated over a treatment period of 1 month. This
design was based on clinical observations that NSAIDs
generally show beneficial effects over a similar timeline.
Previous studies in OA have shown relatively high pla-
cebo effects, and therefore the design of this study was
double blind with a placebo control group. Patients were
enrolled into 3 separate cohorts, with stepwise increases
in the daily dose of the active agent.
Methods
Patients and protocol requirement
To be included in this study patients had to be 50 years of
age or older and have an imaging-confirmed (radiograph
or MRI) diagnosis of OA of the hip or knee. The use of an
NSAID was not permitted in the 7 days prior to the
enrollment visit, and intra-articular steroids could not
have been administered within the previous 30 days. In
addition, no enrolled patient had received intra-articular
hyaluronate injections in the month prior to enrollment.
One individual who had been treated with hyaluronate in
the past had noted no benefit from the series of injec-
tions. Patients had to be able to ambulate sufficiently to
complete a 25 foot walking time. Individuals with signifi-
cant active medical conditions were excluded at the dis-
cretion of the principal investigator. The protocol and the
case report forms were written entirely by the investiga-
tors (NO, VB and GJ). The protocol was approved by the
University of Texas Southwestern Institutional Review
Board and informed consent was obtained from all indi-
viduals prior to the baseline study visit activities. Clinical-
trials.gov identifier is NCT 01010919.
At the baseline visit, a medical history and physical
exam were carried out. The patient completed the follow-
ing self-assessment questionnaires:
McMaster Universities Osteoarthris Index 
(WOMAC)[11,12]
Brief Pain Inventory (BPI)[13]
Modified health assessment questionnaire 
(MHAQ)[14]
Visual analog scale (10 cm) for arthritis pain assess-
ment (VAS)
Each patient also was timed for a 25 foot walk. The fol-
lowing laboratory tests were obtained and sent to the
local clinical laboratory: complete blood count, AST, ALT
and creatinine. Blinded medication provided by the study
sponsor was dispensed. One batch of chicory, chemically
verified for content by a third party laboratory, was used
for all subjects. Randomization of the doses was pre-
determined and built into the packaging, so that each
numbered box of medication was dispensed in sequence
to each enrolled patient. The dispensed capsules each
contained either 200 mg of chicory extract or matching
placebo.
Three study cohorts were enrolled. The first cohort
took one 200 mg capsule three times daily (TID) for a
total dose of 600 mg/day. The second cohort took 2 cap-
sules TID for a total dose of 1200 mg/day and the third
cohort took 3 capsules TID for a total daily dose of 1800
mg/day. Patients randomized to placebo took matching
placebo capsules on the same schedule. To encourage
enrollment, the ratio of active treatment to placebo was
5:3 in cohorts 1 and 2 and 16:8 in cohort 3. One patient
assigned to cohort 3 (and randomized to placebo) took 1
capsule three times daily rather than 3 capsules three
times daily and had 100% compliance with this regimen.
Therefore, blinded data on this individual were analyzed
with cohort 1. With this change in assignment, the final
breakdown of treatment was as follows:
Cohort 1 - 9 Patients: 4 placebo, 5 chicory
Cohort 2 - 8 Patients: 3 placebo, 5 chicory
Cohort 3 - 23 Patients: 8 placebo, 15 chicory
Patients were given diaries to record dosing and use of
the permitted rescue analgesics, acetaminophen alone or
combined with either hydrocodone or codeine. The final
visit was scheduled 4 weeks after the baseline and at this
visit the same tests, instruments and assessments were
carried out. Pill counts were completed and patients were
discharged from the study.
Efficacy assessment and analysis
Efficacy was determined in three domains. The first was
pain, measured as change from baseline in one of the fol-
lowing: WOMAC question #1, WOMAC question #2, or
the mean of items 3,5 and 6 on the BPI. The second
domain was stiffness, measured as change from baseline
in at least one of the following: WOMAC question #3, #4
or #5. The third domain was global functional assessment
measured as change from baseline in walking time,
mHAQ score or the mean of BPI in questions 9a-9g.
Improvement in each domain was defined as a change of
at least 20% compared to the pretreatment baseline, anal-
ogous to the ACR20 response criteria for rheumatoid
arthritis. The efficacy analyses were done with the
blinded data; treatments were not unblinded until after
each individual subject was assigned improved or unim-
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MC). Only after this determination was complete were
the treatment assignments unblinded.
Safety analysis
Changes in laboratory parameters and vital signs were
analyzed by comparing baseline and final visits for each
individual subject.
Statistics
Analysis for efficacy was done using the per protocol
population. Safety analyses included all patients who
received any dose of blinded study medication. For con-
tinuous variables, data were expressed as the mean and
standard error of the mean (SEM). Groups of continuous
variables were compared using a t-test for 2 groups or a 1-
way ANOVA for 3 or more groups. Baseline and final
safety variables were compared using a paired t-test. Dis-
continuous variables were compared using a chi-square




The 40 enrolled patients had an average age of 63 years
and included predominantly females (N = 30) and non-
Hispanic Caucasians (N = 33). The mean BMI for
enrolled subjects was 31, consistent with moderate obe-
sity. There were no significant differences between the
three study groups in these demographic variables (Table
1). Although many patients had arthritis in both the hip
and knee, each subject was asked to identify the one joint
area that currently caused the most problems, and for the
majority of patients (N = 33) this was the knee. Indicators
of disease severity and pain were somewhat worse in
cohort 1, and these differences were statistically signifi-
cant for the walking time (P = 0.009) and the average
score on WOMAC Item #5 (p = 0.047). Baseline labora-
tory tests were all within normal ranges and were not sig-
nificantly different between groups, with the exception of
hemoglobin levels, which were lower in cohort 1 (P =
0.01). All of the participants in cohort 1 were female,
which may have contributed to this result.
Rates of study completion showed an increasing trend
across cohorts: 5/9 (56%) in cohort 1, 6/8 (75%) in cohort
2 and 20/23 (87%) in cohort 3. In cohort 1, two patients
withdrew early due to worsening arthritis pain and two
were lost to followup. In cohort 2, two patients withdrew
due to increased pain, and both were on chicory. No
cohort 3 patients withdrew for worsening arthritis pain,
but two were lost to followup and one discontinued treat-
ment due to an adverse event (described below).
Some patients took permitted rescue analgesics during
the study month. The most commonly used analgesic was
acetaminophen, taken by one patient in cohort 1 who was
assigned to chicory, one patient in cohort 2 who was also
assigned to chicory and five patients in cohort 3, three on
placebo and two on chicory. Narcotic analgesics, either
hydrocodone or codeine in combination with acetamino-
phen, were taken for rescue therapy by two patients in
cohort 1, both assigned to placebo, two in cohort 2, one
each on chicory and placebo. No cohort 3 patient took
narcotic analgesics for rescue. Three patients in cohort 1
took prohibited NSAIDs prior to the final visit due to
increased pain, and these individuals (2 placebo, 1 chic-
ory) were excluded from the efficacy analysis.
Compliance with treatment, defined as taking more
than 80% of prescribed doses as evaluated at visit 2
(excluding patients who did not complete V2), was 83%,
86% and 86% in cohorts 1,2 and 3, respectively.
Efficacy
Efficacy data were analyzed for patients who had com-
pleted both visits without having taken any prohibited
medications prior to either of the two assessments and
who had at least an 80% compliance with the treatment
regimen as determined by pill counts. Using these guide-
lines, numbers of analyzable patients were: 4 in cohort 1,
6 in cohort 2 and 18 in cohort 3. Improvement was
defined as a positive change of at least 20% in at least 2 of
the 3 domains (pain, stiffness and global). Using this defi-
nition, in cohort 1, 2 of 4 patients, 1 each on active treat-
ment and placebo, were improved. In cohort 2, 4 of 6
were improved, 2 each on active treatment and placebo.
In cohort 3, 13 patients were improved, 4 on placebo and
9 on chicory (Figure 1A). In the highest dose group,
cohort 3, the difference between those improved on chic-
ory (9/10; 90%) compared to those who improved on pla-
cebo (4/8; 50%) was close to statistical significance (P =
0.06). In this cohort, 6 of the 9 chicory responders
showed improvement in both the pain and stiffness
domains; two had response in the pain and global
domains and one showed response in the stiffness and
global domains. There was a trend for the visual analog
measure of pain to be decreased in patients on active
treatment in cohort 3, but this was not a statistically sig-
nificant change (Figure 1B).
Safety
Safety measures in patients treated with either chicory or
placebo showed no clinically significant changes between
initial and final determinations of vital signs (HR, BP) or
laboratory measures (CBC, creatinine, AST/ALT) in any
of the cohorts (Tables 2 and 3). A small and statistically
significant change from baseline diastolic blood pressure
(DBP) was observed in the cohort 3 chicory patients; DBP
was elevated at baseline and improved to 90 mm Hg at
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raised by these analyses.
Two patients reported adverse events. One patient in
cohort 2, randomized to placebo, had intermittent nausea
which did not interfere with completing the study or
compliance and which did not require any therapeutic
intervention. One patient in cohort 3, randomized to
chicory, reported headache and diarrhea that started 5
days into the treatment course. This patient discontinued
treatment after 10 days due to these problems and had
complete resolution of all symptoms by the time of the
final visit. The group assignment was not unblinded early
in this individual.
Discussion
OA remains a disorder without available disease-modify-
ing treatments. Pain and limited function are the pre-
dominant manifestations of OA and these are currently
managed with analgesic and anti-inflammatory medica-
tions and physical therapy or surgery, respectively. Due to
the generally older age of OA patients and the high preva-
lence of comorbid conditions in this population, medical
treatments are often limited by unacceptable side effects.
Classic NSAIDs, many of which are now available over-
the-counter, can cause gastrointestinal bleeding, fluid
retention and blood pressure problems, and this limits
therapeutic dosing in many patients. The COX-2 selec-
Table 1: Demographic and disease features at baseline in 3 cohorts
VARIABLES COHORTS P VALUES*
1 2 3
Age (years) 59 ± 2 64 ± 4 65 ± 2 0.28
Gender F/M 9/0 (100%) 5/3 (62.5%) 16/7 (70%) 0.133
Non-Hispanic Caucasian 67% 75% 91% 0.21
BMI 35.3 ± 4.6 30.4 ± 1.6 29.6 ± 1.2 0.20
Knee/Hip 8/1 5/3 20/3 0.60
Walking Time (sec) 12.0 ± 2.6 7.3 ± 0.7 7.7 ± 0.4 0.009
WOMAC Item #1 3.2 ± 0.3 2.4 ± 0.3 3.9 ± 0.4 0.075
WOMAC Item #5 3.2 ± 0.3 2.4 ± 0.3 2.4 ± 0.2 0.047
BPI ** 5.6 ± 0.9 2.6 ± 0.7 3.9 ± 0.4 0.19
Global VAS (mm) 54.5 ± 10.9 31.0 ± 6.7 45.8 ± 4.4 0.15
Modified HAQ (0-3 scale) 1.4 ± 0.2 0.7 ± 0.1 0.8 ± 0.1 0.17
Hemoglobin (g/dL)† 13.0 ± 0.5 14.2 ± 0.4 14.4 ± 0.2 0.016
Creatinine (mg/dL)† 0.77 ± 0.06 0.80 ± 0.09 0.82 ± 0.03 0.74
AST (U/L)† 19 ± 1 23 ± 2 24 ± 2 0.32
*P values for Age and BMI calculated with one-way ANOVA or Fisher's Exact Test.
**BPI Score is mean for items 3-6 and 9(A-G).
† Normal ranges: Hemoglobin 13.2-16.2 g/dL; creatinine 0.7-1.2 mg/dL; AST 13-40 U/L.
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complications, but carry increased risks of cardiovascular
adverse events. These concerns have led to updated
guidelines from the American Geriatrics Society suggest-
ing that anti-inflammatory drugs should not be used on a
chronic basis in treating patients 75 years of age or older
[15]. Analgesics without anti-inflammatory properties,
notably acetaminophen, are often recommended as a
safer alternative. However, many OA patients in clinical
practice find acetaminophen to be generally less effective
than NSAIDs, a finding that also has been confirmed in
controlled clinical trials [3]. Acetaminophen in addition
carries risks of liver toxicity [16]. A consequence of this
situation with available medications is that many patients
with OA do not have adequate control of the pain associ-
ated with their disease. Because reduction in ambulatory
activities that might result from hip and knee OA can
have other health impacts, poor pain control is likely to
result in a significant overall functional decline.
Alternative approaches using various nutraceuticals as
potential arthritis therapeutics, including plant-derived
agents with anti-inflammatory properties, have been
advocated [17,18]. This concept is based in part on the
concept that the health of joint cartilage is dependent
upon the availability of nutritional factors including
essential fatty acids, antioxidants, vitamins and minerals
[7]. Chicory root extract is of interest because it has been
shown to suppress the production of key cytokines and
enzymes involved in inflammation. Preliminary studies
with chicory carried out in the collagen-induced murine
arthritis model showed that this agent reduced joint
swelling with a magnitude similar to the NSAID indo-
methacin (unpublished data, Phytomedics).
Limitations of the current trial include the short dura-
tion of treatment which may have been insufficient to
demonstrate maximal efficacy as well as to detect adverse
events resulting from chronic treatment. A mixed popu-
lation of OA patients was enrolled, including different
sites and use of a per-protocol population rather than an
intention-to-treat (ITT) design, could have introduced
Figure 1 (A) Percent responders in placebo and chicory groups 
and (B) Visual analog pain scores in at baseline and final visits in 
placebo and chicory treatment groups in Cohort 3. (A) Individuals 
in cohorts 1 and 2 were combined for this analysis. The ratios over each 
bar indicate numbers of responders over total numbers of analyzed in-
dividuals in each study group. For Cohort 3, the difference between 
placebo and chicory responses had a corresponding P value of 0.06.
A B
Table 2: Safety measures at visit 1 and visit 2 in patients receiving chicory
Variable Measured Cohort 1 Cohort 2 Cohort 3
(N = 4)* (N = 4) (N = 13)
Visit 1 Visit 2 P** Visit 1 Visit 2 P Visit 1 Visit 2 P
BP Syst (mm Hg) 136 ± 9.3 128 ± 9.9 0.40 144 ± 7.8 141 ± 3.5 0.80 138 ± 5.7 142 ± 5.4 0.39
BP Diast (mm Hg) 83 ± 6.6 82 ± 5.5 0.86 78 ± 10.1 88 ± 3.7 0.46 96 ± 2.3 88 ± 3.4 0.04
HR (BPM) 69 ± 4.2 77 ± 4.6 0.01 74 ± 9.2 76 ± 9.4 0.74 72 ± 3.7 71 ± 4.3 0.65
WBC† (cell/mm3) 6.1 ± 0.6 6.1 ± 0.3 0.48 6.6 ± 1.2 5.9 ± 0.9 0.20 6.9 ± 0.5 6.6 ± 0.2 0.34
Hgb (g/dL) 12.8 ± 0.8 12.6 ± 0.7 0.23 14.4 ± 0.9 14.5 ± 0.8 0.25 14.6 ± 0.2 14.1 ± 0.3 0.02
Creatinine (mg/dL) 0.78 ± 0.08 0.78 ± 0.07 1 0.68 ± 0.11 0.70 ± 0.11 0.39 0.83 ± 0.04 0.84 ± 0.04 0.67
AST (U/L) 17.3 ± 1.8 17.8 ± 0.5 0.81 24.0 ± 3.5 25.0 ± 5.0 0.57 21.9 ± 2.4 22.3 ± 2.4 0.86
* Patients included in this analysis were those receiving chicory who had lab values available at both baseline and final visits. Values represent 
mean and S.E.M.
** P values calculated using paired t-test, V1 vs V2.
†Normal range: WBC 4.1-11.1 × 10/μL.
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treatment effect. The WOMAC measures of outcome did
not follow previously-validated approaches for this
instrument. Future trials will be designed to include a
longer treatment period, more restricted entry criteria for
OA features, validated OA outcome measures (e.g.
OARSI), and ITT analyses to confirm the potential utility
of this treatment.
Data generated in the present small pilot trial suggest
that a proprietary bioactive extract of chicory root might
be efficacious in patients with OA of the hip or knee.
Although the approach used to assess efficacy has not
been validated, this trial is comparable in some respects
to the previously-reported large study of glucosamine and
chondroitin sulfate in which the primary outcome was a
20% reduction in knee pain [6]. Demographic character-
istics were similar in the two studies, and the range of pla-
cebo responses in our patients (50-75%) was comparable
to the 60% rate reported in this previous trial.
Conclusions
These preliminary results are encouraging and will
require verification in a larger study with longer treat-
ment duration to confirm safety and efficacy of this pro-
prietary extract of chicory root for the treatment of OA as
monotherapy or in combination with low doses of
NSAIDs.
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